Department of Paediatrics, Horton General Hospital, Oxford University Hospitals, Banbury, UK.
Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
Rev Med Virol. 2023 Jan;33(1):e2405. doi: 10.1002/rmv.2405. Epub 2022 Nov 15.
Development of a cytomegalovirus (CMV) vaccine is a high priority due to its significant global impact-contributing to mortality in immunosuppressed individuals, neurodevelopmental delay in infected neonates and non-genetic sensorineural hearing loss. The impact of CMV on the general population has been less well studied; however, a wide range of evidence indicates that CMV may increase the risk of atherosclerosis, cancer, immunosenescence, and progression of tuberculosis (TB) and human immunodeficiency virus. Due to the high seroprevalence of CMV worldwide, any modulation of risk by CMV is likely to have a significant impact on the epidemiology of these diseases. This review will evaluate how CMV may cause morbidity and mortality outside of the neonatal and immunosuppressed populations and consider the potential impact of a CMV vaccine on these outcomes.
由于巨细胞病毒（CMV）具有重大的全球影响——导致免疫抑制个体死亡、感染新生儿神经发育迟缓以及非遗传性感觉神经性听力损失，因此开发 CMV 疫苗是当务之急。CMV 对普通人群的影响研究得较少；然而，大量证据表明，CMV 可能会增加动脉粥样硬化、癌症、免疫衰老以及结核病（TB）和人类免疫缺陷病毒进展的风险。由于 CMV 在全球的高血清阳性率，CMV 对风险的任何调节都可能对这些疾病的流行病学产生重大影响。这篇综述将评估 CMV 如何在新生儿和免疫抑制人群之外导致发病和死亡，并考虑 CMV 疫苗对这些结果的潜在影响。
